Physician profile
Brien Rex Miller
NPI 1992066799
$4,826.07
in general payments reported to CMS, 2019-2025
32 companies · $1,219 in 2025
The $1,219 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $529 · 2020: $269 · 2021: $393 · 2022: $670 · 2023: $1,038 · 2024: $707 · 2025: $1,219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,875 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,874.93 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,504.19 | 2019-2025 | |
| Janssen Biotech, INC. | $626.46 | 2021-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $430.85 | 2019-2025 | Entyvio |
| Boston Scientific Corporation | $377.71 | 2019-2025 | Overstitch Nxt Endoscopic Suturing System, Overstitch Endoscopic Suturing System, Overstitch Endoscopic Suturing System Sx |
| Genzyme Corporation | $279.93 | 2022-2025 | |
| Pfizer INC. | $186.34 | 2019-2025 | |
| Qol Medical, LLC | $147.76 | 2019-2024 | Sucraid, Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $135.35 | 2019-2023 | Xifaxan |
| Celgene Corporation | $122.37 | 2021-2024 | Zeposia |
| Enterra Medical, INC. | $116.33 | 2025 | |
| Intercept Pharmaceuticals, INC. | $102.05 | 2022-2025 | Ocaliva |
| Braintree Laboratories, INC. | $100.51 | 2019-2023 | Sutab |
| Gilead Sciences, INC. | $92.51 | 2019-2025 | |
| Lucid Diagnostics INC. | $78.54 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $69.07 | 2024-2025 | Iqirvo |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $63.72 | 2025 | Rezdiffra |
| Regeneron Healthcare Solutions, INC. | $62.25 | 2023-2024 | Dupixent |
| Orphalan INC | $47.20 | 2025 | Cuvrior |
| Allergan, INC. | $44.60 | 2019 | |
| Nestle Healthcare Nutrition INC. | $40.93 | 2022 | |
| Novo Nordisk INC | $32.44 | 2025 | Wegovy |
| Alfasigma USA, INC. | $22.81 | 2022 | |
| Amgen INC. | $21.37 | 2025 | Uplizna |
| Ironwood Pharmaceuticals, INC | $18.04 | 2020 | |
| Medtronic, INC. | $17.88 | 2025 | Interstim |
| Mylan Institutional INC. | $16.70 | 2023 | |
| Ucb, INC. | $16.63 | 2019 | |
| Shire North American Group INC | $15.65 | 2019 | |
| Phathom Pharmaceuticals, INC. | $15.29 | 2024 | Voquezna |
| Daiichi Sankyo INC. | $11.29 | 2019 | |
| Ambu INC. | $9.30 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$14,973.95 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brien Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.